Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Guinea has shown promising development in recent years.
Customer preferences: Guinea has a high demand for pharmaceuticals due to the prevalence of diseases such as malaria, tuberculosis, and HIV/AIDS. The majority of the population relies on public healthcare services, which has led to an increase in demand for affordable and accessible medications. Additionally, there is a growing trend towards natural and traditional medicines, which has led to the emergence of local manufacturers and suppliers.
Trends in the market: The pharmaceuticals market in Guinea has seen a significant increase in foreign investment, particularly from Indian and Chinese companies. This has led to a wider range of medications available in the market, as well as increased competition and affordability. Additionally, the government has taken steps to improve the regulatory framework, which has led to an increase in the quality of medications available.
Local special circumstances: Guinea has a challenging business environment due to political instability, corruption, and a lack of infrastructure. This has led to logistical challenges in the distribution of medications, particularly in rural areas. Additionally, there is a lack of skilled healthcare professionals, which has led to a reliance on foreign medical personnel.
Underlying macroeconomic factors: Guinea has a relatively small economy with a high dependence on the mining sector. The country has faced economic challenges due to fluctuations in global commodity prices, as well as political instability and social unrest. However, the government has taken steps to diversify the economy and improve infrastructure, which has led to increased investment in the healthcare sector. Additionally, the country has a young and growing population, which has led to an increase in demand for healthcare services and medications.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)